In what is becoming a growing trend, another big pharma senior executive has left to take on a position with a growing biotechnology company, this time to the advantage of Cambridge, Massachusetts-based Axcella Health and loss for Swiss giant Novartis. 31 May 2018
ArQule announced on Friday that it was strengthening its management team with the addition of two new senior vice presidents, former Citibank banking director Marc Schegerin and Shirish Hirani, a longstanding VP of drug development at Ariad Pharmaceuticals. 25 May 2018
Norbert Bischofberger has been named chief executive of Kronos Bio, one of the portfolio companies of venture capital firm and merchant bank Two River. 24 May 2018
Sensei Biotherapeutics, a privately-held company known as Panacea Pharmaceuticals until earlier this year, has announced the appointment of John Celebi as chief executive as the company seeks to push forward with its lead cancer vaccine. 16 May 2018
Horizon Discovery’s announcement on the identity of its new chief executive on Monday has been followed on Tuesday by a major drop in the share price of the gene editing company. 9 May 2018
Nordic Nanovector saw its share plunge 9.66% to 4.21 euros as markets opened this mornings, after the Norway-based biotech firm revealed that its chief executive, Luigi Costa, will step down from the post by mutual agreement with the board of directors. 5 April 2018
US gene therapy developer Abeona Therapeutics has lured one of the most experienced names in rare diseases to become its new chief executive. 3 April 2018
Celgene Corp on Monday announced that Scott Smith, president and chief operating officer (COO), is leaving the company effective immediately. 3 April 2018
A couple of additions have been made to the executive team of Orchard Therapeutics, a privately-held clinical-stage biotech based in the UK and USA. 21 March 2018
Swedish biotech firm Karolinska Development's portfolio company Modus Therapeutics, which is focused on sickle cell disease (SCD) and malaria, announces that Dr John Öhd has been appointed to a position as chief medical officer (CMO). 15 March 2018
French biotech company Cellectis announced today that Dr Mathieu Simon is retiring as executive vice president and chief operating officer, effective immediately. 14 March 2018
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024